Sensus Healthcare, Inc. (NASDAQ:SRTS) Sees Significant Decrease in Short Interest

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 845,600 shares, a decline of 28.3% from the February 13th total of 1,180,000 shares. Currently, 6.2% of the company's stock are short sold. Based on an average trading volume of 325,600 shares, the days-to-cover ratio is currently 2.6 days.

Sensus Healthcare Stock Performance

Shares of SRTS traded down $0.04 during mid-day trading on Thursday, reaching $4.74. The company had a trading volume of 76,965 shares, compared to its average volume of 307,378. Sensus Healthcare has a 52 week low of $3.09 and a 52 week high of $9.33. The company has a market capitalization of $78.19 million, a price-to-earnings ratio of 11.85 and a beta of 1.28. The firm has a 50-day moving average price of $5.90 and a 200 day moving average price of $6.61.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. As a group, research analysts forecast that Sensus Healthcare will post 0.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. bought a new position in Sensus Healthcare in the 4th quarter valued at approximately $27,000. Barclays PLC purchased a new position in Sensus Healthcare in the fourth quarter worth about $35,000. Truvestments Capital LLC bought a new stake in shares of Sensus Healthcare during the 3rd quarter valued at about $32,000. BNP Paribas Financial Markets purchased a new stake in shares of Sensus Healthcare during the 4th quarter valued at about $47,000. Finally, Geode Capital Management LLC lifted its stake in shares of Sensus Healthcare by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company's stock worth $849,000 after purchasing an additional 11,525 shares during the period. 25.30% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

SRTS has been the subject of a number of research analyst reports. HC Wainwright raised their target price on Sensus Healthcare from $11.00 to $12.00 and gave the company a "buy" rating in a research note on Monday, February 10th. Lake Street Capital dropped their target price on shares of Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.